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Abstract
Themain objective of this research workwas to study the association of serum levels of growth factors (GF) and SDF-1αwith the
functional outcome and reduction of lesion volume in ischemic stroke patients. In this multicenter study, 552 patients with non-
lacunar stroke (male, 62.1%; mean age, 68.2 ± 11.4) were included within 24 h from symptom onset. The main outcome variable
was good functional outcome (modified Rankin Scale [mRS] ≤ 2) at 12 months. Secondary outcome variable was infarct volume
(in mL) after 6 ± 3months. Serum levels of VEGF, Ang-1, G-CSF, BDNF, and SDF-1αweremeasured by ELISA at admission, 7
± 1 days, at 3 ± 1 months, and 12 ± 3 months. Except for BDNF, all GF and SDF-1α serum levels showed a peak value at day 7
and remained elevated during the first 3 months (all p < 0.01). High serum levels at day 7 of VEGF (OR, 19.3), Ang-1 (OR, 14.7),
G-CSF (OR, 9.6), and SDF-1α (OR, 28.5) were independently associated with good outcome at 12 months (all p < 0.0001). On
the other hand, serum levels of VEGF (B, − 21.4), G-CSF (B, − 14.0), Ang-1 (B, − 13.3), and SDF-1α (B, − 44.6) measured at
day 7 were independently associated with lesion volume at 6 months (p < 0.01). In summary, high serum levels of VEGF, Ang-1,
G-CSF, and SDF-1α at day 7 and 3 months after ischemic stroke are associated with good functional outcome and smaller
residual lesion at 1 year of follow-up.
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Introduction
Improvement of the management of stroke patients, especially
in developed countries, has contributed to the reduction in
mortality and morbidity rates observed in recent decades.
However, the incidence of stroke has not followed this same
trend showing a continuous increase in developed countries
[1]. Besides, the demographic change expected in Europe for
the next 50 years suggests that this situation will become
worse [2].
In addition, the ceiling of reperfusion treatment is already
close (only 20% of with ischemic stroke patients can benefit
from these treatments in highly specialized hospitals, whose
and their effectiveness does not exceed 50–60%) [3].
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Moreover, new neuroprotective approaches are limited, main-
ly due to a narrow therapeutic window. Therefore, the identi-
fication of new targets for ischemic stroke is mandatory for
clinicians and researchers.
The medium-long-term prognosis (weeks and/or months)
of patients with ischemic stroke will depend on the size and
topography of the infarction, the speed and efficiency of the
acute phase therapeutic measures, and the degree of
neurorepair processes mediated by the patient’s cerebral plas-
ticity mechanisms [4, 5].
One of the main options for enhancing the mechanisms of
cellular plasticity is cellular therapy that, favors by the extraor-
dinary advance of the investigation of cellular biology, repre-
sents a hopeful therapeutic target for ischemic stroke. In this
regard, the use of embryonic stem cells, induced pluripotent
stem cells, and adult stem cells have demonstrated therapeutic
effects in preclinical models of cerebral ischemia, and to a lesser
extent in humans mainly through the mesenchymal stem cells.
However, the mechanisms underlying cellular therapy are not
well understood, since most of the transplanted cells disappear
within a fewweeks, and this therapy is not free from potentially
serious complications [6–8]. It is possible that effectiveness of
cellular therapy is based on trophic factors and other bioactive
substances that modify the cerebral microenvironment and
stimulate the development of the patient’s own cellular niches
[9–11]. Therefore, the stimulation of cerebral plasticity by using
growth factors (GF), which participate in a coadjutant way in
neurogenesis, neoangiogenesis, gliagenesis, and synaptogene-
sis mechanisms, may constitute a more translational therapeutic
approach from the lab to the bedside [12, 13].
Unlike the great existing knowledge on GF in preclinical
models of cerebral ischemia, there is a gap in studies in clinical
practice which may be one of the reasons why clinical trials
with GF such as granulocyte colony-stimulating factor (G-
CSF) have failed [13, 14]. Thus, it is necessary to know better
the relationship between growth factors and the prognosis of
ischemic stroke patients at long term.
For this purpose, we designed a multicenter and observa-
tional study of a cohort of patients with acute ischemic stroke
in order to study the association of serum levels of GF (vas-
cular endothelial growth factor [VEGF], [G-CSF], brain-
derived neurotrophic factor [BDNF], angiopoietin 1 [Ang-
1]) and stromal-derived factor-1α [SDF-1α] with the func-
tional outcome and reduction of lesion volume of ischemic
stroke patients during a follow-up period of 1 year.
Materials and Methods
Study Population and Patient Characteristics
We have conducted a multicenter and observational study of a
cohort of ischemic stroke patients, of less than 24 h from
stroke onset, consecutively admitted to Stroke Units of 6
Spanish hospitals. The period of recruitment of the patients
was carried out in the first half of 2014. Patients without di-
agnostic confirmation by neuroimaging, lacunar infarcts, pre-
vious disability (modified Rankin Scale > 1), cancer, severe
systemic or metabolic disease, and inflammatory or infectious
disease in the previous 15 days and patients who received
investigational drugs in clinical trials were excluded.
Clinical Variables
All patients were admitted to an acute Stroke Unit and treated
according to the European Stroke Organisation guidelines
[15]. The follow-up period was 1 year, including 2 visits at 3
± 1 months and at 12 ± 3 months.
Medical history recording potential vascular risk factors,
blood and coagulation test, 12-lead electrocardiogram, chest
X-ray, and carotid ultrasonography were performed at admis-
sion. Stroke subtype was classified according to the TOAST
criteria [16], and stroke severity was assessed by a certified
neurologist using the National Institute of Health Stroke Scale
(NIHSS) at admission, 48 h, 3 ± 1, and 12 ± 3 months.
Functional outcome was evaluated at 3 ± 1 and 12 ± 3 months
using the modified Rankin Scale (mRS). Good functional out-
come was defined as a mRS score ≤ 2. Physiotherapy/
rehabilitation was collected during the hospitalization as well
as the first 3 or 12 months of follow-up period.
Neuroimaging Variables
Cerebral computed tomography (CT) studies were carried out
at admission, between 4th and 7th days and after 3 months.
Patients who received reperfusion treatment had another CT
study before and at 24–36 h after treatment. Hemorrhagic
transformation (HT) was assessed in the follow-up CT. HT
was defined as symptomatic when it was associated with early
neurological deterioration (worsening > 4 points in the NIHSS
during the first 48 h from stroke onset). Lesion volume was
calculated on the follow-up CT by using the formula 0.5 × A ×
B × C, where A and B are the largest perpendicular diameters,
and C is the number of 1-cm thick sections that contain the
lesion. All neuroimaging evaluations were made by investiga-
tors who had no knowledge of the patients’ clinical and labo-
ratory results.
Outcome Variables
The primary endpoint was good functional outcome (mRS
score ≤ 2) at 12 ± 3 months; as secondary variables, we con-
sidered the good functional outcome (mRS score ≤ 2) at 3 ± 1
months and the lesion volumes between 4th and 7th days and
after 3 months.
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Laboratory Tests
Biochemistry, hematology, and coagulation test were assessed
in the central laboratory of each participating hospital.
However, the growth factors and SDF-1α determinations of
the total patients included in each of 6 hospitals were per-
formed in the Clinical University Hospital of Santiago de
Compostela. The GF selected for this study were VEGF, G-
CSF, BDNF, Ang-1, and SDF-1α. For these molecular deter-
minations, venous blood samples were collected in Vacutainer
tubes (Becton Dickinson, San Jose, CA, USA) at admission, 7
± 1 days, 3 ± 1, and 12 ± 3 months. After allowing to clot for
60min, blood samples were centrifuged at 3000×g for 10min,
and the serum was immediately aliquoted, frozen, and stored
at − 80 °C until analysis. Serum levels of VEGF, G-CSF, and
BDNF (Boster Biological Technology, Encyclopedia Circle
Fremont, CA, USA), Ang-1 (Adipo Bioscience Inc., Santa
Clara, CA, USA), and SDF-1α (R&D Systems Inc.,
Minneapolis, MN, USA) were quantified using commercial
ELISA kits following instructions provided by commercial
houses. The coefficients of intra-assay variation were VEGF,
4.4%; G-CSF, 5.2%; BDNF, 4.8%; Ang-1, 4.7%; and SDF-
1α, 3.6%; the coefficients of inter-assay variation were VEGF,
6.9%; G-CSF, 8.3%; BDNF, 7.9%; Ang-1, 8.1%; and SDF-
1α, 7.2%. The determinations were performed in an indepen-
dent laboratory that did not have access to clinical or neuro-
imaging data.
Statistical Analysis
According to unpublished own previous results, 42% (p1 =
0.42) of ischemic stroke patients have a mRS > 2 at discharge
and do not show a significant improvement during a 1 year of
follow-up period. It has been calculated that if a sample of 545
individuals (n = 545) is included, an accuracy of 4.12% (ω =
0.41) will be obtained by means of a normal 95% asymptotic
confidence interval (γ = 0.95) bilateral (c = 2). For the calcu-
lation of the sample size, EPIDAT version 4.2 (www.sergas.
es/Saude-publica/EPIDAT) was used.
Results were expressed as percentages for categorical var-
iables and as mean (SD) or median and interquartile range for
the continuous variables depending on their distribution.
Kolmogorov-Smirnov test was used for testing normality.
Chi-square or Fisher test was performed to study categorical
variables. The continuous were studied with the Student’s t or
the Mann-Whitney tests. Spearman’s or Pearson’s analyses
were used to test bivariate correlations. ANOVAwas used to
analyze the relationship between stroke subtypes and growth
factors. Mixed analysis of variance (MANOVA) was used to
study the effect of time, and groups (good and poor outcome)
by time (baseline to 12 months) interactions on GF and SDF-
1α levels. The influence of growth factors on functional out-
come and the lesion volume was assessed by logistic
regression and multiple lineal regression models, respectively.
The models were constructed considering the baseline vari-
ables related to each outcome variable. Results were expressed
as adjusted odds ratios (OR) or Beta estimate with their 95%
confidence intervals (95% CI). The statistical analysis was
conducted using IBM SPSS Statistic, version 20 (SPSS Inc.
Chicago, IL, USA).
Results
Sample Description
A total of 650 patients with a first-ever ischemic stroke of less
than 24 h from symptoms onset was included in the study. Six
patients were excluded due to lack of diagnostic confirmation,
39 patients were lacunar infarcts, 4 patients showed previous
disability (mRS > 1), and 12 patients were included in clinical
trials during the acute phase. Moreover, 37 patients were loss
during follow-up or suffered a recurrent stroke. Therefore, a final
sample of 552 patients (male, 62.1%; mean age, 68.2 ± 11.4
years) was valid for testing the primary endpoint of the study.
On the other hand, 28 patients died during the first month/
week/admission, 37 at 3 months, and 84 at the end of the
follow-up period of 12 months. Additionally, blood samples
were not obtained in 8 patients at 3 months, and 23 patients
had not blood sample at 1 year of follow-up. So, a baseline
serum sample was available in 552 patients, at 7 days in 524,
Fig. 1 Screening and enrollment into the study
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at 3 months in 507, and finally 445 patients had serum sample
at 12 months (Fig. 1).
Regarding neuroimaging, CT at admission was performed
in all; the second CT performed between 4th and 7th days was
available in 537 patients, while the final CTwas completed in
409 patients after 3 months (average time, 6.3 ± 2.7 months
after admission).
NIHSS at admission was 11 [6, 17]. A total of 198 patients
(35.9%) received intravenous fibrinolytic treatment within the
first 4.5 h. Following TOATS criteria, 13.9% of patients were
diagnosed as atherothrombotic stroke, 50.0% cardioembolic,
and 36.1% as undetermined origin. The median (quartiles) of
mRS at 3 months was 2 [1, 3] and 1 [0, 3] at 12 months.
Temporal Profile of GF and SDF-1α Levels
Except for BDNF, all GF and SDF-1α serum levels showed a
peak value at day 7 (all p < 0.01) (Fig. 2). The increase in
percentage of serum levels of GF during the first week were as
follows: VEGF, 77.4 ± 111.8% (p < 0.0001); G-CSF, 67.2 ±
98.8% (p < 0.0001); BDNF, − 2.1 ± 44.3% (p = 0.349); Ang-
1, 69.6 ± 120.6% (p < 0.0001); and SDF-1α, 29.6 ± 31.4% (p
< 0.0001). At 3 months, only an increase of VEGF (p <
0.0001) and G-CSF (p < 0.0001) serum levels in relation to
the basal concentration persisted; the concentrations of BDNF
(p = 0.312), Ang-1 (p = 0.632), and SDF-1α (p = 0.078) were
similar to baseline. By contrast, at 12 months, serum levels of
VEGF (p = 0.169) and G-CSF (p = 0.418) were similar to
those at baseline, but BDNF (p < 0.0001), Ang-1 (p =
0.016), and SDF-1α (p < 0.0001) levels were lower.
Primary Outcome: Good Functional Outcome at 12
Months
Table 1 shows the main characteristics of patients by functional
outcome groups. Three hundred and fifty-one (68.6%) patients
Fig. 2 (a–e) Temporal profile of
GF (VEGF, G-CSF, BDNF, Ang-
1) and SDF-1α levels at admis-
sion, 7 ± 1 days, 3 ± 1 months,
and 12 ± 3 months. All GF and
SDF-1α serum levels showed a
peak value at day 7 and remained
elevated during the first 3 months
(all p < 0.01), except for BDNF
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showed good functional outcome at 12 months. Patients with
good functional outcome were younger, showed milder stroke
severity, and smaller lesion volume at 4th–7th day.
Furthermore, fibrinolytic treatment, rehabilitation, and statins
treatment previous and during acute phase of stroke were more
frequent in the group of patients with good outcome.
On the other hand, with the exception of BDNF, all GF and
SDF-1α showed a different expression profile in patients with
good and poor outcome. Mean (SD) levels of VEGF, G-CSF,
and SDF-α at day 7 and 3 months as well as Ang-1 at day 7
were significantly higher in patients with good functional out-
come (Fig. 3).
In the logistic regression analysis, serum levels of SDF-1α
(OR, 28.5; 95% CI 13.2–81.2), VEGF (OR, 19.3; 95% CI
10.7–231.9), Ang-1 (OR, 14.7; 95% CI 4.4–61.9), and G-
CSF (OR, 9.6, 95% CI 6.9–55.3) at day 7 were independently
associated with good functional outcome at 12 months after
adjustment by significant variables of bivariate analysis
showed in Table 1. Moreover, serum levels of SDF-1α (OR,
20.2; 95% CI 8.1–57.1), VEGF (OR, 10.9; 95% CI 2.3–50.7),
and G-CSF (OR, 8.9; 95% CI 4.4–34.7) at 3 months were also
independently associated with good functional outcome at 12
months (Table 2).
Secondary Outcome: Good Functional Outcome at 3
Months
Three hundred and forty-seven patients (62.9%) had good
functional outcome at 3 months. Bivariate analysis showed
similar results to those obtained for the functional prognosis
at 12 months (data not shown). The logistic regression analy-
sis showed that serum levels of SDF-1α (OR, 20.6; 95% CI
9.2–46.1), VEGF (OR, 12.6; 95% CI 5.7–27.7), Ang-1 (OR,
9.1; 95% CI 4.0–20.8), and G-CSF (OR, 6.2; 95% CI 3.2–
21.3) at day 7 were independently associated with good func-
tional outcome at 3 months.
Secondary Outcome: Lesion Volume at 4th–7th Days
and at 6 Months
Figures 4 and 5 show the correlations between GF and SDF-
1α serum levels, measured at admission and the lesion
Table 1 Baseline clinical
characteristics, vascular risk
factors, stroke subtype,
biochemical parameters and
neuroimaging findings in patients
with good or poor outcome at 12
± 3 months
Good outcome n = 351 Poor outcome n = 201 p value
Age, years 66.9 ± 11.6 69.6 ± 9.4 0.001
Males, % 61.3 63.7 0.586
History of hypertension, % 58.4 71.6 0.002
History of diabetes, % 19.4 27.9 0.026
Smoking habit, % 26.8 13.4 < 0.0001
Alcohol consumption, % 15.4 9.5 0.051
History of hyperlipidemia, % 41.3 55.2 0.002
History of ischemic heart disease, % 15.4 16.9 0.631
History of atrial fibrillation, % 24.8 34.8 0.014
History of heart failure, % 10.3 9.5 0.883
Previous disability (mRS < 1) 0 (0, 0) 0 (0, 0) 0.448
Statins prior to stroke, % 31.3 21.1 0.008
Axillary temperature admission, °C 36.4 ± 0.5 36.6 ± 0.5 0.080
Glucose levels, mg/dL 127.6 ± 50.4 143.2 ± 43.5 < 0.0001
Leukocytes, × 103/mmc 9.3 ± 6.1 9.1 ± 2.4 0.100
Fibrinogen, mg/dL 404.7 ± 133.4 439.6 ± 160.1 0.003
NIHSS at admission 8 (5, 13) 18 (14, 20) < 0.0001
Fibrinolytic treatment, % 39.0 30.3 0.043
Infarct volume (4th to 7th day), mL 16.8 ± 29.8 98.2 ± 94.1 < 0.0001
Hemorrhagic transformation, % 13.4 16.9 0.263
Statins after stroke, % 70.9 62.2 0.038
TOAST 0.113
Atherothrombotic, % 11.7 17.9
Cardioembolic, % 48.1 53.2
Indeterminate, % 40.2 28.9
Rehabilitation during-hospital, % 27.1 33.0 0.145
Rehabilitation during 12 months, % 10.3 18.9 0.007
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volumes at days 4–7, the correlation between GF and SDF-1α
serum levels at day 7, and lesion volume at 6 months. Only
admission serum levels of SDF-1α (r = − 0.373) were associ-
ated with lesion volume at 4th–7th day. However, serum
levels at day 7 of VEGF (r = − 0.324), G-CSF (r = − 0.140),
Ang-1 (r = − 0.216), and SDF-1α (r = − 0.580), but not
BDNF, had a significant correlation with the lesion volume
after 3 months.
In the multiple linear regression model, adjusted for those
significant variables associated to lesion volume in the univar-
iate analysis (history of arterial hypertension, alcohol con-
sumption, history of atrial fibrillation, fibrinolytic treatment,
and NIHSS at admission), serum levels of VEGF (B, − 21.4),
G-CSF (B, − 14.0), Ang-1 (B, − 13.3), and SDF-1α (B, −
44.6) measured at day 7 were independently associated with
lesion volume at 6 months (all p < 0.01). By contrast, only
SDF-1α levels (B, − 29.6) at admission were independently
associated to lesion volume at 4th–7th day (Table 3).
Discussion
This prospective and multicenter study shows a relationship
between serum GF and SDF-1α and brain injury in patients
Fig. 3 (a–e) Temporal profile serum levels of GF (VEGF, G-CSF, BDNF, Ang-1) and SDF-1α in patients with good or poor outcome at 12 ± 3 months
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with ischemic stroke. The increase of serum levels of VEGF,
Ang-1, G-CSF, and SDF-1α at day 7 and 3 months after
ischemic stroke was independently associated with a good
functional outcome at 3 and 12 months. This favorable effect
on the primary variable was supported by positive effects on
the reduction of lesion volume after 3 months. Importantly,
these effects remained significant after adjustment for well-
recognized prognostic factors such as age, lesion volume,
stroke severity, and fibrinolytic treatment.
Serum levels of VEGF, G-CSF, Ang-1, and SDF-1α
showed a similar biological pattern, with a peak value at day
7 and remained elevated levels during the first 3 months. Of all
of them, SDF-1αwas the biomarker more powerful associated
to the outcome variables (functional recovery and residual
lesion volume). Conversely, BDNF had a different profile,
showing a progressive decrease of its serum levels from the
stroke onset. In fact, BDNF levels were not associated with
any of the endpoints analyzed in this study, neither with de
infarct volume, nor with the functional outcome during a
follow-up period of 1 year. The role of BDNF in the patho-
physiology of ischemic stroke has been evaluated in animal
and clinical studies, where the results were not conclusive.
Previous studies [17, 18] have presented a relationship be-
tween a baseline and isolated BDNF determination and
outcome of ischemic stroke patients (in our series there was
a slight non-significant association with a lower infarct vol-
ume); moreover, the increase of the BDNF expression after
rehabilitation has also been reported [19]. Other studies sup-
ported the lack of correlation between serumBDNF levels and
lesion size or recovery in stroke patients [20, 21]. However, it
is important to note that different research works have showed
that serum BDNF may not accurately reflect BDNF concen-
trations in the brain due to endothelial dysfunction [22, 23].
BDNF levels could be also influenced by a variety of factors
including platelet count, gender, smoking status, depression,
and age and Val66Met polymorphism [21, 24–28]. Therefore,
further studies are necessary to elucidate the potential role of
BDNF as a GF able to induce recovery in ischemic stroke
patients.
The selection of the GF analyzed in this study was per-
formed due to previous studies, mainly in preclinical
models of cerebral ischemia, since there is a gap in studies
in clinical practice which may be one of the reasons why
clinical trials with GF such as G-CSF have failed [13, 14].
Specifically, VEGF is a potent angiogenic factor, inducible
by hypoxia, which plays an important role in the vascular
response to ischemia, promoting the formation of new ce-
rebral blood vessels (neovascularization) [29–34].
Table 2 Adjusted and non-
adjusted OR of good outcome at
12 months for serum levels of GF
(VEGF, G-CSF, BDNF, Ang-1)
and SDF-1α at admission, day 7 ±
1, 3 ± 1 months, and 12 ± 3
months
Growth factors Non-adjusted Adjusted*
OR 95% CI p OR 95% CI p value
VEGF at admission 1.7 1.3–2.3 0.001 1.7 1.5–4.9 0.001
VEGF at 7 days 26.6 14.1–48.7 < 0.0001 19.3 10.7–231.9 < 0.0001
VEGF at 3 months 22.3 11.7–42.5 < 0.0001 10.9 2.3–50.7 < 0.0001
VEGF at 12 months 3.1 2.0–4.9 < 0.0001 1.6 1.1–10.0 < 0.0001
G-CSF at admission 0.8 0.5–1.1 0.255 0.85 0.4–1.5 0.603
G-CSF at 7 days 15.9 8.8–28.9 < 0.0001 9.59 6.9–55.3 < 0.0001
G-CSF at 3 months 6.5 3.7–11.4 < 0.0001 8.99 4.4–34.7 < 0.0001
G-CSF at 12 months 1.4 0.9–2.3 0.124 1.11 0.5–2.3 0.781
BDNF at admission 1.3 0.7–2.1 0.305 0.69 0.2–1.9 0.494
BDNF at 7 days 2.2 1.4–3.6 0.001 2.69 0.9–6.9 0.139
BDNF at 3 months 1.9 1.1–3.1 0.017 1.48 0.5–3.6 0.395
BDNF at 12 months 1.3 0.7–2.4 0.337 1.75 0.5–5.1 0.308
Ang-1 at admission 0.8 0.5–1.2 0.279 1.47 0.7–2.7 0.230
Ang-1 at 7 days 29.6 15.4–57.1 < 0.0001 14.72 4.4–61.9 < 0.0001
Ang-1 at 3 months 1.5 0.9–2.2 0.062 1.57 0.7–3.4 0.251
Ang-1 at 12 months 1.3 0.8–1.9 0.293 1.26 0.6–2.6 0.536
SDF-1α at admission 22.1 10.1–126.8 < 0.0001 16.25 10.1–87.2 < 0.0001
SDF-1α at 7 days 31.9 15.8–214.1 < 0.0001 28.53 13.2–81.1 < 0.0001
SDF-1α at 3 months 29.6 10.3–103.8 < 0.0001 20.19 8.1–57.2 < 0.0001
SDF-1α at 12 months 2.3 1.0–5.3 0.043 2.09 0.6–7.8 0.269
*Adjusted by age, history of hypertension, history of diabetes, smoking habit, history of hyperlipidemia, history
of atrial fibrillation, statins prior to stroke, glucose levels, fibrinogen, NIHSS at admission, fibrinolytic treatment,
infarc volume, rehabilitation during 12 months
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Likewise, VEGF has been also implicated as a factor pro-
moting neurogenesis in the adult brain, increasing the pro-
liferation and differentiation of endothelial and neuronal
progenitor cells [9, 29, 35].
G-CSF induces the mobilization of hematopoietic stem
cells from the bone marrow to the injured brain regions, re-
ducing the volume of the infarct and improving neuronal plas-
ticity and vascularization, which translates into a better func-
tional recovery [36–38]. Also inhibits apoptosis and stimu-
lates the differentiation of neuronal progenitor cells, inducing
neurogenesis.
BDNF is a neurotropic factor involved in ischemia-
induced neurogenesis processes, and increased recruitment
of endogenous progenitors to injured brain regions, medi-
ating repair mechanisms and neuronal plasticity [39].
BDNF has also been shown to induce synaptogenesis,
morphogenesis, and plasticity of dendritic spines, resulting
in synapses with functionality [40, 41].
The functionality of GF depends, to a large extent, on the
relationship between them and between the cells that induce
their expression. Thus, VEGF induces the release of BDNF
from endothelial cells [42] and stimulates the formation of
pericytes [31]. Similarly, Ang-1 and SDF-1α could be the link
between neurogenesis and angiogenesis, promote neuroblast
migration, and post-stroke functional recovery [43, 44].
The usefulness of the knowledge about the potential role of
GF in the recovery of the cerebral lesion caused by the ische-
mia is not conditioned only by a better understanding of the
underlying mechanisms that mediate brain repair but also be-
cause they may imply more translational therapies than those
mediated by cellular therapy. In this regard, drugs that induce
the expression of GF are already known, such as 4α-phorbol
Fig. 4 Scatterplots between GF
(VEGF, G-CSF, BDNF, Ang-1)
and SDF-1α serum levels mea-
sured at admission and 7 ± 1 days
and the lesion volumes at 4th–7th
day
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12,13-didecanoate (an endothelial receptor agonist), 15(S)-
hydroxyeicosat acid (arachidonic acid metabolite) [34], or
guanosine [45]. In addition, GF have already been tested in
clinical trials, although with modest results. The G-CSF has
shown a slight functional improvement, but not of the neuro-
logical deficit [14].
Fig. 5 Scatterplots between GF
(VEGF, G-CSF, BDNF, Ang-1)
and SDF-1α serum levels mea-
sured at 7 ± 1 days and after 6 ± 3
months
Table 3 Adjusted* B of lesion
volume at 4th–7th day and after 3
months for serum levels of GF
(VEGF, G-CSF, BDNF, Ang-1)
and SDF-1α at admission and day
7 ± 1
Admission Lesion volume (4th–7th day) 7th day Infarct volume (at 6 month)
B 95% CI p value B 95% CI p value
VEGF − 4.9 − 13.6 to 3.79 0.269 VEGF − 21.6 − 29.6 to − 3.7 < 0.0001
G-CSF − 1.4 − 11.1 to 21.42 0.125 G-CSF − 14.0 − 23.6 to − 4.7 0.003
BDNF 3.5 − 11.6 to 18.56 0.650 BDNF − 11.2 − 23.4 to 1.1 0.074
Ang-1 − 3.3 − 13.60 to 7.01 0.530 Ang-1 − 13.3 − 24.5 to − 2.0 0.021
SDF-1α − 29.2 − 41.95 to − 16.50 < 0.0001 SDF-1α − 44.6 − 54.2 to − 34.9 < 0.0001
*Adjusted by age, history of atrial fibrillation, NIHSS at admission, and, fibrinolytic treatment
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This study has some limitations. First, patients were admit-
ted to Stroke Units of 6 Spanish hospitals, and hematology
and coagulation test were assessed in the central laboratory of
each participating hospital. However, patients were treated
according to the European Stroke Organisation guidelines
[15]. In addition, the growth factors and SDF-1α determina-
tions of the total patients were performed only in one hospital.
Second, to have normal healthy subjects as a control group
(cohort of age, comorbidity) would give more value to the
results presented. Three, it is important to note that many
conditions affect the level of growth factors, for example,
subject exercise or age [21, 24–28]. Although given the mean
age of patients (68.2 ± 11.4 years), their physical activity or
exercise was low or moderate. Four, we did not take the loca-
tion of the lesion into account in our analysis, only the lesion
volume. Five, we have not considered in the analysis the dif-
ferent reperfusion treatments (intravenous or intraarterial fibri-
nolysis, thrombectomy, or both procedures). Six, the design of
our study does not allow concluding mechanistic aspects on
the role of growth factors in the prognosis of patients with
cerebral infarction. However, its results open the possibility
to design new more translational clinical trials. Short-term
administrations of growth factors during the acute or subacute
phases of stroke are not expected to modify the prognosis of
patients. According to the temporal expression profiles of GF
obtained, an administration started within the first week and
prolonged during the first 3 months after the stroke seems a
more translational approach. However, for this objective, new
therapeutic formulations will be necessary [13].
Summary
High serum levels of VEGF, Ang-1, G-CSF, and SDF-1α at day
7 and 3 months after ischemic stroke are associated with good
functional outcome and smaller residual lesion at 1 year of fol-
low-up. New clinical trials, not focused in acute phase of stroke,
should be conducted in order to clarify whether GF may be able
to promote functional recovery in ischemic stroke patients.
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